TSXV - Free Realtime Quote CAD

Ventripoint Diagnostics Ltd. (VPT.V)

0.1450

+0.0050

+(3.57%)

As of 9:30:03 AM EDT. Market Open.

Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System

TORONTO, ONTARIO - February 27, 2025 (NEWMEDIAWIRE) - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) is pleased to announce that it has received U.S. Food and Drug Administration ("FDA") 510(k) clearance for the ...

NewMediaWire last month

VPTDF
Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology

TORONTO - (NewMediaWire) - October 24, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTCQB:VPTDF) a leader in whole heart analysis technology, is pleased to announce CE Mark certification for its latest offering, VM...

NewMediaWire 6 months ago

VPTDF
Ventripoint Diagnostics Second Quarter 2024 Earnings: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2023)

Ventripoint Diagnostics ( CVE:VPT ) Second Quarter 2024 Results Key Financial Results Revenue: CA$30.7k (up by CA$26.8k...

Simply Wall St. 7 months ago

VPTDF
Ventripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning Technology

TORONTO, Ontario - (NewMediaWire) - August 21, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) a leader in whole heart analysis, is pleased to announce that it has received a Medical Device License from He...

NewMediaWire 8 months ago

VPTDF
Ventripoint Diagnostics First Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2023)

Ventripoint Diagnostics ( CVE:VPT ) First Quarter 2024 Results Key Financial Results Net loss: CA$1.19m (loss narrowed...

Simply Wall St. 10 months ago

VPTDF
Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration

VMS+4.0 submitted to FDA on May 1 for clearance Ventripoint will market new advances after FDA clearanceTORONTO, Ontario - (NewMediaWire) - May 6, 2024 - TheNewswire - May 6, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Com...

NewMediaWire 11 months ago

VPTDF
Ventripoint Diagnostics Full Year 2023 Earnings: CA$0.031 loss per share (vs CA$0.031 loss in FY 2022)

Ventripoint Diagnostics ( CVE:VPT ) Full Year 2023 Results Key Financial Results Net loss: CA$4.87m (flat on FY 2022...

Simply Wall St. 11 months ago

VPTDF

Performance Overview

Return	VPT.V	S&P/TSX Composite index (^GSPTSE)
YTD	+45.00%	+0.40%
1-Year	-36.96%	+12.52%
3-Year	-54.69%	+17.04%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ventripoint Diagnostics Ltd. (VPT.V)

Ventripoint Diagnostics Announces U.S. FDA 510(k) Clearance for VMS+(TM) 4.0 Automated Radiological Image Processing Software/System

Ventripoint Receives EU CE Mark for Next Generation, AI-powered Heart-scanning Technology

Ventripoint Diagnostics Second Quarter 2024 Earnings: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2023)

Ventripoint Receives Medical Device License from Health Canada to Sell Next Generation, AI-powered, Heart-scanning Technology

Ventripoint Diagnostics First Quarter 2024 Earnings: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2023)

Ventripoint's Next Generation, AI-powered Heart-scanning Technology Submitted to U.S Food and Drug Administration

Ventripoint Diagnostics Full Year 2023 Earnings: CA$0.031 loss per share (vs CA$0.031 loss in FY 2022)

Performance Overview